Sir,
We have read with interest the article which was published in your journal titled: 'Prediction of subclinical atherosclerosis by serum osteoprotegerin in premenopausal women with systemic lupus erythematous: correlation of osteoprotegerin with monocyte chemotactic protein-1', 1 which concludes that, in premenopausal women with systemic lupus erythematosus (SLE), the increased serum levels of osteoprotegerin (OPG) correlate with a greater carotid intima-media thickness (CIMT). We would like to comment on the results of a similar study carried out in Granada (a city in the south of Spain). Our results are based on a cross-sectional study including 68 women diagnosed with SLE attending our practice between November 2008 and November 2012. The serum levels of OPG were measured with an enzyme-linked immunosorbent assay kits (OPG ELISA BIOMEDICA-GRUPPE, Wien, Austria). The subclinical atherosclerosis (SA) was evaluated by means of CIMT, the presence of carotid plaque and ankle brachial index (ABI). The average OPG levels were 82.8 AE 58 standard deviation (SD) (pg/ ml). With regards to subclinical atherosclerosis, 8.9% of the patients presented atherosclerotic plaques in carotids and 31% (21/68) presented a pathological ABI (<1%). The average CIMT of the total of the sample was 0.68 mm. The comparative results between premenopausal and menopausal patients are reflected in Table 1 . On evaluating the relationship between the levels of OPG of our sample patients and the SA variables, no statistically significant relationship was found between OPG and ABI (p ¼ 0.96), or between OPG and CIMT (p ¼ 0.15). The CIMT correlated with age (p ¼ 0.001), family history of cardiovascular disease (FHCVD; p ¼ 0.022) and meno-pausal status (p ¼ 0.001). The sample was divided into quartiles of OPG, as in the case of Park et al., 1 but no statistically significant relationship was found between the quartiles of OPG and the studied variables (age, CIMT, tobacco use, FHCVD, arterial hypertension, dyslipidemia and diabetes mellitus).
The increase in the incidence of cardiovascular illnesses in patients with lupus has been widely studied. Different studies try to clarify if this increase is exclusively explained by the increase in cardiovascular risk factors in the lupus population, 2, 3 or if there are other factors, related to the inflammatory status, which contribute to the greater incidence of these types of pathologies in these patients. 4, 5 OPG behaves as a predictor of the risk of complications in hospitalized patients with coronary syndrome, 6 and as a predictor of coronary atherosclerotic disease or cardiovascular morbidity and mortality. 7, 8 In our study, unlike the findings of Park et al., 1 no statistically-significant relationship was found between OPG levels and subclinical arteriosclerosis, measured by different techniques (ABI, CIMT). However, there were differences between the levels measured both of OPG and CIMT between premenopausal and menopausal women, which could be related to the changes occurring during the menopause and the increase in cardiovascular risk factors. On the other hand, our study is limited with respect to Park et al., 1 in the number of lupus patients (61 vs 181) and type of patients (premenopausal and menopausal women compared to premenopausal). These differences may account for the different results.
However, more studies are required to evaluate the role of these new biochemical markers as early arteriosclerosis detectors in patients with lupus.
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